Searched for
ERIS LIFESCIENCES ACQUIRES
Eris Lifesciences shares in focus on move to acquire Swiss Parenterals in Rs 423 crore dealEris Lifesciences is set to fully acquire its injectable unit, Swiss Parenterals. The deal involves a share swap valued at Rs 423.3 crore. ...- Eris Lifesciences reports 41% year-on-year rise in net profit in Q1Eris Lifesciences reported a robust 41% YoY increase in net profit, reaching Rs 125 crore for the first quarter, driven by strong performan...
- Stocks in news: IndiGo, Apollo Hospitals, Hyundai, TCS, NMDC, Laurus LabsApollo Hospitals' Hyderabad-based arm Apollo Health and Lifestyle Limited (AHLL) has acquired a controlling stake in Lucknow-based Care Dia...
- Eris Lifesciences net profit drops 4.5% to Rs 89 crore in Q1FY25Eris acquired Biocon Biologics' domestic branded formulation business for Rs 1,242 crore in Q4FY24 and dermatology and nephrology units in ...
- Eris Lifesciences Q1 Results: Net dips 4.5% YoY at Rs 89 croreEris Lifesciences on Friday said its consolidated profit after tax declined by 4.5 per cent year on year to Rs 89 crore for the quarter end...
- Stocks in news: Paytm, Vedanta, IIFL Finance, RIL, Blue StarVedanta's plan to demerge its businesses into separate entities could face hurdles from its minority shareholders and creditors, according ...
- Eris acquires 51 pc stake in Swiss Parenterals for Rs 637.5 crEris Lifesciences on Tuesday said it has acquired a 51 per cent stake in Swiss Parenterals for Rs 637.5 crore. Ahmedabad-based Swiss Parent...
- Eris Lifesciences acquires Biocon Biologics' nephro, derma units for Rs 366 croreEris Lifesciences has announced that it has reached a definitive agreement to acquire the dermatology and nephrology branded formulations b...
- Eris Lifesciences acquires 9 dermatology brands from Dr Reddy's for Rs 275 crThe transaction will be financed through borrowings and will achieve financial closure in the next few days, the drug firm said. In a separ...
- Eris buys nine derma brands from Glenmark for Rs 340 croreThe nine brands have sales of Rs 87.30 crores for FY22, which represents valuation of 3.9x of the sales of these brands in FY22. The acquir...
- Eris Lifesciences to buy some dermatology brands from Glenmark PharmaThe deal for the portfolio that has an annual revenue base of 850 million rupees, will be financed through borrowings, and the transaction ...
- Eris Lifesciences to buy some dermatology brands from Glenmark PharmaThe deal, through Eris' dermatology focused unit, is for the purchase of nine brands, including Onabet, Halobate, Sorvate, and Demelan for ...
- Eris Lifesciences scouting for acquisitions to diversify bizThrough acquisition of Strides domestic formulations portfolio in 2017, Eris Lifesciences got a toehold in the neurology and psychiatry seg...
- Eris Lifesciences enters licensing deal with Biocon for insulin glargineThe launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its reve...
- USV in talks with Novartis to buy Jalra Trademark for Rs. 200 CroreMumbai-based drugmaker USV Pvt Ltd is in advanced discussions to acquire the trademark for antidiabetes drug Jalra from Novartis for a deal...
- Citigroup maintains buy on Eris Lifesciences, raises target price to Rs 750The brokerage has raised FY21 and FY22 estimated EPS by 2.5% and 3% respectively.
- Accumulate Eris Lifesciences, target Rs 704: Prabhudas LilladherAccumulate Eris Lifesciences Ltd. at a price target of Rs 704.
- Eris Lifesciences, Shasun Strides shares rise on Rs 500 crore dealThe India branded generics business being divested by Strides had sales of Rs 181 core FY 2017, the statement said.
- Eris signs definitive pact to buy Strides’ India portfolio for Rs 500 crThe acquisition is Eris’s fourth and the largest buyout in the last 18 months. With this, the company will be among the top ten companies i...
- Eris Life to acquire Strides' India business for Rs 500 croreBoards of both the companies are expected to meet on Saturday and a formal announcement is due as early as on Monday, people with knowledge...
Load More
